Skip to main content
Clinical Trials/NL-OMON50838
NL-OMON50838RecruitingPhase 4

Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease. - GENPAD

Academisch Medisch Centrum0 sites2,276 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Enrollment
2,276

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - age > 16 years
  • - obtained written informed consent
  • - indication for monotherapy clopidogrel 75mg once daily
  • - ankle-brachial index < 0.9 and/or toe brachial index < 0.5
  • - current or previous symptoms due to insufficient vascularization of one or
  • two lower extremities, including intermittent claudication, pain at rest and/or
  • gangrene (Rutherford category 1-6)
  • - consulting a vascular surgeon for diagnosis, treatment and/or follow-up of
  • PAD symptoms

Exclusion Criteria

  • - known CYP2C19*2 and *3 status
  • - treated with coumarins, Non-vitamin K Oral Anti-Coagulants, unfractionated
  • heparin, low molecular weight heparins or double antiplatelet therapy for other
  • indications
  • - contraindication for clopidogrel, acetylsalicylic acid and/or rivaroxaban
  • - life expectancy of less than 1 year
  • - pregnant or breastfeeding women
  • - unable to give informed consent

Investigators

Similar Trials

Genotype-guided strategy for... | Clinical Trial